Several important studies have highlighted a lack of efficacy of cetuximab and panitumumab in metastatic CRC with KRAS mutations, in particular KRAS exon 2 mutations but also KRAS exon 3 and 4 mutations, and similar observations were made for NRAS mutations [46,47,48,49]. The gene discussed is KRAS; the disease is colorectal carcinoma.